Shailender Bhatia
About
Shailender Bhatia is a scholar working on Oncology, Aerospace Engineering and Electrical and Electronic Engineering.
According to data from OpenAlex, Shailender Bhatia has authored 152 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Oncology, 48 papers in Aerospace Engineering and 47 papers in Electrical and Electronic Engineering. Recurrent topics in Shailender Bhatia's work include Polyomavirus and related diseases (87 papers), Antenna Design and Analysis (48 papers) and Full-Duplex Wireless Communications (44 papers). Shailender Bhatia is often cited by papers focused on Polyomavirus and related diseases (87 papers), Antenna Design and Analysis (48 papers) and Full-Duplex Wireless Communications (44 papers). Shailender Bhatia collaborates with scholars based in United States, France and Germany. Shailender Bhatia's co-authors include Paul Nghiem, John A. Thompson, Scott S. Tykodi, Kelly G. Paulson, Upendra Parvathaneni, Omid Hamid, Jayasri G. Iyer, Célèste Lebbé, Howard L. Kaufman and Isaac Brownell and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.
In The Last Decade
Shailender Bhatia
137 papers receiving 6.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shailender Bhatia United States | 40 | 5.3k | 2.1k | 1.8k | 1.6k | 921 | 152 | 6.3k | ||
| Patrick Terheyden Germany | 23 | 2.8k 0.5× | 813 0.4× | 662 0.4× | 815 0.5× | 606 0.7× | 107 | 3.4k | ||
| Marie‐Françoise Avril France | 45 | 3.6k 0.7× | 596 0.3× | 518 0.3× | 1.5k 0.9× | 2.0k 2.2× | 161 | 6.2k | ||
| Axel zur Hausen Germany | 40 | 3.5k 0.7× | 851 0.4× | 723 0.4× | 514 0.3× | 2.7k 3.0× | 140 | 6.6k | ||
| Douglas R. Fullen United States | 32 | 3.6k 0.7× | 646 0.3× | 595 0.3× | 650 0.4× | 2.1k 2.3× | 130 | 5.5k | ||
| Karl D. Lewis United States | 41 | 4.9k 0.9× | 599 0.3× | 484 0.3× | 1.5k 0.9× | 4.0k 4.3× | 177 | 7.8k | ||
| Jochen H. Lorch United States | 32 | 2.9k 0.5× | 451 0.2× | 366 0.2× | 601 0.4× | 1.0k 1.1× | 121 | 5.4k | ||
| Melissa Pulitzer United States | 30 | 1.9k 0.4× | 656 0.3× | 632 0.4× | 432 0.3× | 501 0.5× | 145 | 3.2k | ||
| Jonathan S. Zager United States | 46 | 4.4k 0.8× | 323 0.2× | 266 0.1× | 1.2k 0.8× | 1.9k 2.0× | 288 | 6.3k | ||
| Evan J. Lipson United States | 41 | 5.9k 1.1× | 264 0.1× | 151 0.1× | 2.2k 1.4× | 1.4k 1.5× | 126 | 7.7k | ||
| Uwe Trefzer Germany | 30 | 2.7k 0.5× | 211 0.1× | 182 0.1× | 1.1k 0.7× | 2.8k 3.1× | 78 | 4.5k |
Countries citing papers authored by Shailender Bhatia
Since
Specialization
Citations
This map shows the geographic impact of Shailender Bhatia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shailender Bhatia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shailender Bhatia more than expected).
Fields of papers citing papers by Shailender Bhatia
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shailender Bhatia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shailender Bhatia. The network helps show where Shailender Bhatia may publish in the future.
Co-authorship network of co-authors of Shailender Bhatia
This figure shows the co-authorship network connecting the top 25 collaborators of Shailender Bhatia. A scholar is included among the top collaborators of Shailender Bhatia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shailender Bhatia. Shailender Bhatia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hippe, Daniel S., Tomoko Akaike, Natalie J. Miller, et al.. (2025). Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials. Journal for ImmunoTherapy of Cancer. 13(9). e012660–e012660.
2.
Bhatia, Shailender, Suzanne L. Topalian, William H. Sharfman, et al.. (2025). Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Journal of Clinical Oncology. 43(9). 1137–1147.
3.
Akaike, Tomoko, Daniel S. Hippe, Matthew W. Gilmour, et al.. (2025). Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy. British Journal of Dermatology. 193(6). 1221–1231.
4.
Paulson, Kelly G., Song Y. Park, Shailender Bhatia, Daniel S. Hippe, & Paul Nghiem. (2025). Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy. Journal of the American Academy of Dermatology. 93(1). 89–94.
5.
Lai, Carol, Petros Grivas, Shailender Bhatia, et al.. (2025). Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. European Heart Journal - Case Reports. 9(2). ytaf019–ytaf019.
6.
Tachiki, Lisa, Daniel S. Hippe, Thomas H. Pulliam, et al.. (2025). Risk of disease progression after discontinuing immunotherapy in 105 patients with Merkel cell carcinoma who responded to PD-1 pathway blockade. Journal for ImmunoTherapy of Cancer. 13(8). e012123–e012123.
7.
Read, Charlotte, Shailender Bhatia, & Mariam Totonchy. (2025). Programmed cell death 1 blockade in the setting of severe ocular sarcoidosis: Cancer immunotherapy in a patient with autoimmunity. JAAD Case Reports. 62. 43–45.
8.
Miller, Natalie J., Wenwen Chen, Evan Hall, et al.. (2024). TRICK-MCC: A proof-of-concept, investigator-initiated study of combination therapy with anti–PD-1, anti–LAG-3, and anti–TIM-3 in participants with advanced or metastatic PD-(L)1 refractory Merkel cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9618–TPS9618.
9.
Pulliam, Thomas H., Peter H. Goff, Kimberly S. Smythe, et al.. (2024). Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses. Journal for ImmunoTherapy of Cancer. 12(10). e009803–e009803.
10.
Grignani, Giovanni, Piotr Rutkowski, Célèste Lebbé, et al.. (2023). 1146P Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Annals of Oncology. 34. S686–S686.
11.
Bhatia, Shailender, et al.. (2022). Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. Journal for ImmunoTherapy of Cancer. 10(8). e004904–e004904.
12.
Park, Song Y., Tomoko Akaike, Upendra Parvathaneni, et al.. (2021). How We Treat Merkel Cell Carcinoma: Within and Beyond Current Guidelines. Future Oncology. 17(11). 1363–1377.
13.
Akaike, Tomoko, Austin Anderson, Fatemeh Behnia, et al.. (2020). High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. British Journal of Dermatology. 184(2). 319–327.
14.
Lewis, Christopher W., Daniel S. Hippe, Kristina Lachance, et al.. (2019). Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. Cancer Medicine. 9(4). 1374–1382.
15.
Bhatia, Shailender, Natalie Miller, Rima M. Kulikauskas, et al.. (2019). Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. Clinical Cancer Research. 26(3). 598–607.
16.
Atkins, Michael B., F. Stephen Hodi, John A. Thompson, et al.. (2018). Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research. 24(8). 1805–1815.
17.
Segal, Neil H., Aiwu Ruth He, Toshihiko Doi, et al.. (2018). Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clinical Cancer Research. 24(8). 1816–1823.
18.
Bhatia, Shailender, Natalie J. Miller, Hailing Lu, et al.. (2018). Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. Clinical Cancer Research. 25(4). 1185–1195.
19.
Miller, Natalie, Candice D. Church, Steven P. Fling, et al.. (2018). Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy. Journal for ImmunoTherapy of Cancer. 6(1). 131–131.
20.
Paulson, Kelly G. & Shailender Bhatia. (2018). Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide. Journal of the National Comprehensive Cancer Network. 16(6). 782–790.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Patrick Terheyden Breakdown of academic impact, for papers by Marie‐Françoise Avril Breakdown of academic impact, for papers by Axel zur Hausen Breakdown of academic impact, for papers by Douglas R. Fullen Breakdown of academic impact, for papers by Karl D. Lewis Breakdown of academic impact, for papers by Jochen H. Lorch Breakdown of academic impact, for papers by Melissa Pulitzer Breakdown of academic impact, for papers by Jonathan S. Zager Breakdown of academic impact, for papers by Evan J. Lipson Breakdown of academic impact, for papers by Uwe Trefzer